Ashida, Akira http://orcid.org/0000-0001-5972-946X
Matsumura, Hideki
Shimono, Akihiko
Fujii, Yuko
Yamazaki, Satoshi
Funding for this research was provided by:
Alexion Pharmaceuticals
Article History
Received: 10 June 2022
Accepted: 27 October 2022
First Online: 6 November 2022
Declarations
:
: Employment: Akihiko Shimono (Alexion Pharma GK), Stock options: Akihiko Shimono (Alexion, AstraZeneca Rare Disease), Advisory role: Akira Ashida (Alexion Pharma GK), Honoraria: Akira Ashida (Alexion Pharma GK), Grants Received: Akira Ashida (Alexion Pharma GK,).
: The survey was conducted in accordance with the ethical principles contained within the 1964 Declaration of Helsinki, and the ethical guidelines for epidemiological studies issued by the Ministry of Health, Labour and Welfare, Japan. The survey was approved by the ethics board of Osaka Medical College (approved number: 2675–2) before the study commenced.
: For this type of study, formal consent was not required.